One of the adverse effects of diabetes is damage to the kidney function (known as diabetic nephropathy), which results in the abnormal presence of proteins in the patient’s urine.
Currently, the commonly used method for diagnosing diabetes is to measure plasma glucose levels. This is an invasive and vulnerable method, so there is still a need to find an effective, non-invasive and rapid way to detect diabetes.
The essence of the offer of the invention is a set of two peptides (substrates), with fluorogenic properties. These peptides are hydrolysed in the presence of proteolytic enzymes (ADAM10 and ADAM17) released and present in the urine of diabetic patients.
The diagnostic potential of a method based on the assessment of the hydrolytic activity of proteolytic enzymes in human urine by measuring the fluorogenic activity of their substrates has shown that the activity of proteolytic enzymes in the urine of diabetic patients is significantly higher than in people with normal blood levels.
